MedWatch

Novartis beats expectations for third quarter

Core earnings per share ended the period at a higher level than analysts' estimates for Novartis's Q3.

Photo: Arnd Wiegmann/Reuters/Ritzau Scanpix

Novartis finishes the third quarter of the year better than analysts had anticipated, including outperforming in core earnings per share (EPS), reports Bloomberg News.

Consensus estimates collected by Bloomberg News put Novartis's net sales at USD 13bn, but Novartis has marginally exceeded that figure with reported Q3 net sales figures of USD 13.03bn.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs